Rhinovirus strain 16 (University of Virginia)

Rhinovirus strain 16 (University of Virginia) is an experimental viral challenge agent consisting of wild-type Human Rhinovirus strain 16 (HRV-16). Originally isolated from a healthy volunteer at the University of Virginia, this specific strain has been manufactured under Good Manufacturing Practice (GMP) conditions for use in controlled human infection models (CHIM). It is primarily used as a research tool to induce standardized respiratory infections in clinical trial participants, particularly those with asthma, to study the mechanisms of virus-induced asthma exacerbations and to evaluate the efficacy of potential therapeutic interventions like omalizumab. The virus is typically administered intranasally to trigger upper and lower respiratory tract symptoms, allowing for the study of airway inflammation and bronchial hyperreactivity in a controlled clinical setting.

Other names

Human Rhinovirus 16Rhinovirus (strain 16)HRV-16 challenge agentHRV16 challenge agentHRV 16 challenge agentRhinovirus strain 16-University of Virginia-asthma